Standalone EBIDTA margin (before forex (gain)/loss) at 27.10% in Q1FY22 as against 39.65% in Q1FY21. Consolidated EBIDTA margin at 27.36% in Q1FY22 as against 38.44% in Q1FY21. Standalone Net Profit down 37% at Rs284.72cr. Consolidated Net Profit down 31% at Rs306.67cr.
Total Formulations revenue stood at Rs1054.77cr in Q1FY22, a rise of 11% compared to Rs953.05cr in Q1FY21. Total APIs revenue was at Rs414.42cr in Q1FY22, a decline of 19% compared to Rs513.29cr in Q1FY21.
Ipca is a fully integrated pharmaceutical company with a strong thrust on exports. Ipca is vertically integrated and produces Finished Dosage Forms (PDFs) and Active Pharmaceutical Ingredients (APIs).
Ipca Laboratories Ltd ended at Rs2,130.10 up by Rs42.55 or 2.04% from its previous closing of Rs2,087.55 on the BSE. The company stock touched day's high of Rs2242.50 per piece near 52-week high of Rs2245.55 per piece on Thursday.